Physiomics Awarded New Contract by Numab

Physiomics PLC

14 April 2026

 

14 April 2026

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded New Contract by Numab Therapeutics

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its valued and long-standing client, Numab Therapeutics AG ("Numab Therapeutics").

Numab Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under this new contract, Physiomics will develop a mechanistic pharmacokinetic-pharmacodynamic (PK/PD) modelling framework to support proof-of-concept activities for a new programme within Numab Therapeutics' oncology pipeline.

Throughout the project, Physiomics will apply quantitative approaches to interpret emerging data, optimise experimental design and development strategy, and inform key go/no-go decision-making. The project is expected to commence in April 2026 and complete in Q3 2026.

This project further strengthens Physiomics' established collaboration with Numab Therapeutics and highlights the ongoing integration of model-informed approaches to support strategic decision-making across Numab Therapeutics' pipeline.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to extend our collaboration with Numab Therapeutics to provide insights that can support robust proof-of-concept decision-making for this early oncology programme."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.   

 

END